Leptomeningeal Metastatic L858R EGFR-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib

References

• Lee SJ, Il LJ, Nam DH, et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol. 2013;8(2):185–191. doi:10.1097/JTO.0b013e3182773f21
   PubMed Web of Science ®Google Scholar
• Kuiper JL, Hendriks LE, van der Wekken AJ, et al. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis. Lung Cancer. 2015;89(3):255–261. doi:10.1016/j.lungcan.2015.05.023
   PubMed Web of Science ®Google Scholar
• Eichler AF, Kahle KT, Wang DL, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010;12(11):1193–1199. doi:10.1093/neuonc/noq076
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339–346.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101(36):13306–13311. doi:10.1073/pnas.0405220101
   PubMed Web of Science ®Google Scholar
• Jorge SEDC, Kobayashi SS, Costa DB. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res. 2014;47(11):929–939. doi:10.1590/1414-431X20144099
   PubMed Web of Science ®Google Scholar
• Yi HG, Kim HJ, Kim YJ, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer. 2009;65(1):80–84. doi:10.1016/j.lungcan.2008.10.016
   PubMed Web of Science ®Google Scholar
• Cheng L, Alexander RE, MacLennan GT, et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol. 2012;25(3):347–369. doi:10.1038/modpathol.2011.215
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247. doi:10.1158/1078-0432.CCR-12-2246
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE. AZD9291 in epidermal growth factor receptor inhibitor-Resistant non-small-cell lung cancer. Transl Lung Cancer Res. 2016;5(1):92–94. doi:10.3978/j.issn.2218-6751.2015.07.19
   PubMed Web of Science ®Google Scholar
• Uemura T, Oguri T, Okayama M, et al. Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: a case report. Mol Clin Oncol. 2017;6(4):525–528. doi:10.3892/mco.2017.1181
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2017;376(7):629–640. doi:10.1056/NEJMoa1612674
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou VA, Mok TS, Han JY, et al. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020;31(11):1536–1544. doi:10.1016/j.annonc.2020.08.2100
   PubMed Web of Science ®Google Scholar
• Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR -mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Yang JCH, Kim SW, Kim DW, et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol. 2020;38(6):538–547. doi:10.1200/JCO.19.00457
   PubMed Web of Science ®Google Scholar
• Yang JC-H, Kim D-W, Kim S-W, et al. Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a Phase I study. J Clin Oncol. 2016;34(15_suppl):9002. doi:10.1200/JCO.2016.34.15_suppl.9002
   Web of Science ®Google Scholar
• How J, Mann J, Laczniak AN, Baggstrom MQ. Pulsatile Erlotinib in EGFR-positive non–small-cell lung cancer patients with leptomeningeal and brain metastases: review of the literature. Clin Lung Cancer. 2017;18(4):354–363. doi:10.1016/j.cllc.2017.01.013
   PubMed Web of Science ®Google Scholar
• Masuda T, Hattori N, Hamada A, et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol. 2011;67(6):1465–1469. doi:10.1007/s00280-011-1555-6
   PubMed Web of Science ®Google Scholar
• Katayama T, Shimizu J, Suda K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol. 2009;4(11):1415–1419. doi:10.1097/JTO.0b013e3181b62572
   PubMed Web of Science ®Google Scholar
• Yang H, Yang X, Zhang Y, et al. Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib failure. Target Oncol. 2015;10(1):135–140. doi:10.1007/s11523-014-0326-9
   PubMed Web of Science ®Google Scholar
• Lee E, Keam B, Kim DW, et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol. 2013;8(8):1069–1074. doi:10.1097/JTO.0b013e318294c8e8
   PubMed Web of Science ®Google Scholar
• Ballard P, Yates JWT, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130–5140. doi:10.1158/1078-0432.CCR-16-0399
   PubMed Web of Science ®Google Scholar
• Li J, Liu X, Yuan C. Treatment response to osimertinib in a patient with leptomeningeal metastasis from lung adenocarcinoma following failure of gefitinib and erlotinib: a case report. Mol Clin Oncol. 2018;9(3):321–324. doi:10.3892/mco.2018.1666
   PubMed Web of Science ®Google Scholar
• Tsang MW. Osimertinib 160 mg daily for advanced non‐small cell lung cancer with leptomeningeal metastasis: a case report. Asia Pac J Clin Oncol. 2019;15(S6):5–7. doi:10.1111/ajco.13246
   PubMed Web of Science ®Google Scholar
• Li H, Yu T, Huang M, Guo A, Qian X, Yin Z. Treatment response to osimertinib in EGFR-Mutated leptomeningeal metastases from non-small cell lung cancer: a case series. Onco Targets Ther. 2019;12:7785–7790. doi:10.2147/OTT.S199452
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Naoki K, Manabe T, et al. Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. Onco Targets Ther. 2018;11:3335–3343. doi:10.2147/OTT.S161745
   PubMed Web of Science ®Google Scholar
• Stockley T, Souza CA, Cheema PK, et al. Evidence-based best practices for EGFR T790M testing in lung cancer in Canada. Curr Oncol. 2018;25(2):163–169. doi:10.3747/co.25.4044
   PubMed Web of Science ®Google Scholar